Adipocyte Piezo1 mediates obesogenic adipogenesis through the FGF1/FGFR1 signaling pathway in mice.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
08 05 2020
Historique:
received: 16 10 2019
accepted: 01 04 2020
entrez: 10 5 2020
pubmed: 10 5 2020
medline: 18 8 2020
Statut: epublish

Résumé

White adipose tissue (WAT) expansion in obesity occurs through enlargement of preexisting adipocytes (hypertrophy) and through formation of new adipocytes (adipogenesis). Adipogenesis results in WAT hyperplasia, smaller adipocytes and a metabolically more favourable form of obesity. How obesogenic WAT hyperplasia is induced remains, however, poorly understood. Here, we show that the mechanosensitive cationic channel Piezo1 mediates diet-induced adipogenesis. Mice lacking Piezo1 in mature adipocytes demonstrated defective differentiation of preadipocyte into mature adipocytes when fed a high fat diet (HFD) resulting in larger adipocytes, increased WAT inflammation and reduced insulin sensitivity. Opening of Piezo1 in mature adipocytes causes the release of the adipogenic fibroblast growth factor 1 (FGF1), which induces adipocyte precursor differentiation through activation of the FGF-receptor-1. These data identify a central feed-back mechanism by which mature adipocytes control adipogenesis during the development of obesity and suggest Piezo1-mediated adipocyte mechano-signalling as a mechanism to modulate obesity and its metabolic consequences.

Identifiants

pubmed: 32385276
doi: 10.1038/s41467-020-16026-w
pii: 10.1038/s41467-020-16026-w
pmc: PMC7211025
doi:

Substances chimiques

Insulin 0
Interleukin-6 0
Ion Channels 0
Piezo1 protein, mouse 0
Fibroblast Growth Factor 1 104781-85-3
Receptor, Fibroblast Growth Factor, Type 1 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2303

Commentaires et corrections

Type : ErratumIn

Références

Heymsfield, S. B. & Wadden, T. A. Mechanisms, pathophysiology, and management of obesity. N. Engl. J. Med. 376, 254–266 (2017).
pubmed: 28099824
Czech, M. P. Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23, 804–814 (2017).
pubmed: 28697184 pmcid: 6048953
Bluher, M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15, 288–298 (2019).
Gonzalez-Muniesa, P. et al. Obesity. Nat. Rev. Dis. Prim. 3, 17034 (2017).
pubmed: 28617414
Berry, R., Jeffery, E. & Rodeheffer, M. S. Weighing in on adipocyte precursors. Cell Metab. 19, 8–20 (2014).
pubmed: 24239569
Wang, Q. A., Tao, C., Gupta, R. K. & Scherer, P. E. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat. Med. 19, 1338–1344 (2013).
pubmed: 23995282 pmcid: 4075943
Ghaben, A. L. & Scherer, P. E. Adipogenesis and metabolic health. Nat. Rev. Mol. Cell. Biol. 20, 242–258 (2019).
Cristancho, A. G. & Lazar, M. A. Forming functional fat: a growing understanding of adipocyte differentiation. Nat. Rev. Mol. cell Biol. 12, 722–734 (2011).
pubmed: 21952300 pmcid: 7171550
Arner, P. et al. Variations in the size of the major omentum are primarily determined by fat cell number. J. Clin. Endocrinol. Metab. 98, E897–E901 (2013).
pubmed: 23543656
Spalding, K. L. et al. Dynamics of fat cell turnover in humans. Nature 453, 783–787 (2008).
pubmed: 18454136
Stenkula, K. G. & Erlanson-Albertsson, C. Adipose cell size: importance in health and disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 315, R284–R295 (2018).
pubmed: 29641234
Rodeheffer, M. S., Birsoy, K. & Friedman, J. M. Identification of white adipocyte progenitor cells in vivo. Cell 135, 240–249 (2008).
pubmed: 18835024
Tang, W. et al. White fat progenitor cells reside in the adipose vasculature. Science 322, 583–586 (2008).
pubmed: 18801968 pmcid: 2597101
Vishvanath, L. et al. Pdgfrbeta+ mural preadipocytes contribute to adipocyte hyperplasia induced by high-fat-diet feeding and prolonged cold exposure in adult mice. Cell Metab. 23, 350–359 (2016).
pubmed: 26626462
Jeffery, E., Church, C. D., Holtrup, B., Colman, L. & Rodeheffer, M. S. Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity. Nat. Cell Biol. 17, 376–385 (2015).
pubmed: 25730471 pmcid: 4380653
Ross, S. E. et al. Inhibition of adipogenesis by Wnt signaling. Science 289, 950–953 (2000).
pubmed: 10937998
Tang, Q. Q. & Lane, M. D. Adipogenesis: from stem cell to adipocyte. Annu Rev. Biochem. 81, 715–736 (2012).
pubmed: 22463691
Rosen, E. D. & MacDougald, O. A. Adipocyte differentiation from the inside out. Nature reviews. Mol. cell Biol. 7, 885–896 (2006).
Coste, B. et al. Piezo proteins are pore-forming subunits of mechanically activated channels. Nature 483, 176–181 (2012).
pubmed: 22343900 pmcid: 3297710
Zhao, Q. et al. Structure and mechanogating mechanism of the Piezo1 channel. Nature 554, 487–492 (2018).
pubmed: 29469092
Saotome, K. et al. Structure of the mechanically activated ion channel Piezo1. Nature 554, 481–486 (2018).
pubmed: 29261642
Lewis, A. H. & Grandl, J. Mechanical sensitivity of Piezo1 ion channels can be tuned by cellular membrane tension. Elife 4, e12088 (2015).
Cox, C. D. et al. Removal of the mechanoprotective influence of the cytoskeleton reveals PIEZO1 is gated by bilayer tension. Nat. Commun. 7, 10366 (2016).
pubmed: 26785635 pmcid: 4735864
Syeda, R. et al. Piezo1 Channels are inherently mechanosensitive. Cell Rep. 17, 1739–1746 (2016).
pubmed: 27829145 pmcid: 5129625
Li, J. et al. Piezo1 integration of vascular architecture with physiological force. Nature 515, 279–282 (2014).
pubmed: 25119035 pmcid: 4230887
Cahalan, S. M. et al. Piezo1 links mechanical forces to red blood cell volume. Elife 4, e07370 (2015).
Gudipaty, S. A. et al. Mechanical stretch triggers rapid epithelial cell division through Piezo1. Nature 543, 118–121 (2017).
pubmed: 28199303 pmcid: 5334365
Coste, B. et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science 330, 55–60 (2010).
pubmed: 20813920 pmcid: 3062430
Colom, A. et al. A fluorescent membrane tension probe. Nat. Chem. 10, 1118–1125 (2018).
pubmed: 30150727 pmcid: 6197433
McLaughlin, T. et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 50, 1707–1715 (2007).
pubmed: 17549449
Gustafson, B., Hedjazifar, S., Gogg, S., Hammarstedt, A. & Smith, U. Insulin resistance and impaired adipogenesis. Trends Endocrinol. Metab. 26, 193–200 (2015).
pubmed: 25703677
Jonker, J. W. et al. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391–394 (2012).
pubmed: 22522926 pmcid: 3358516
Prudovsky, I. et al. Folding of fibroblast growth factor 1 Is critical for its nonclassical release. Biochemistry 55, 1159–1167 (2016).
pubmed: 26836284
Hoch, R. V. & Soriano, P. Context-specific requirements for Fgfr1 signaling through Frs2 and Frs3 during mouse development. Development 133, 663–673 (2006).
pubmed: 16421190
Miwa, H. & Era, T. Generation and characterization of PDGFRalpha-GFPCreERT2 knock-In mouse line. Genesis 53, 329–336 (2015).
pubmed: 25884589
Krueger, K. C., Costa, M. J., Du, H. & Feldman, B. J. Characterization of Cre recombinase activity for in vivo targeting of adipocyte precursor cells. Stem Cell Rep. 3, 1147–1158 (2014).
Jeffery, E. et al. Characterization of Cre recombinase models for the study of adipose tissue. Adipocyte 3, 206–211 (2014).
pubmed: 25068087 pmcid: 4110097
Mejhert, N. et al. Mapping of the fibroblast growth factors in human white adipose tissue. J. Clin. Endocrinol. Metab. 95, 2451–2457 (2010).
pubmed: 20228166
Hutley, L. et al. Fibroblast growth factor 1: a key regulator of human adipogenesis. Diabetes 53, 3097–3106 (2004).
pubmed: 15561939
He, J. et al. Fibroblast growth factor-1 (FGF-1) promotes adipogenesis by downregulation of carboxypeptidase A4 (CPA4)—a negative regulator of adipogenesis implicated in the modulation of local and systemic insulin sensitivity. Growth Factors 34, 210–216 (2016).
pubmed: 28209092
Murthy, S. E., Dubin, A. E. & Patapoutian, A. Piezos thrive under pressure: mechanically activated ion channels in health and disease. Nat. Rev. Mol. Cell Biol. 18, 771–783 (2017).
pubmed: 28974772
Wu, J., Lewis, A. H. & Grandl, J. Touch, tension, and transduction—the function and regulation of Piezo ion channels. Trends Biochem Sci. 42, 57–71 (2017).
pubmed: 27743844
Pope, B. D., Warren, C. R., Parker, K. K. & Cowan, C. A. Microenvironmental control of adipocyte fate and function. Trends Cell Biol. 26, 745–755 (2016).
pubmed: 27268909 pmcid: 6788628
Shoham, N. & Gefen, A. Mechanotransduction in adipocytes. J. Biomech. 45, 1–8 (2012).
pubmed: 22112919
Del Marmol, J. I., Touhara, K. K., Croft, G. & MacKinnon, R. Piezo1 forms a slowly-inactivating mechanosensory channel in mouse embryonic stem cells. Elife 7, e33149 (2018).
Zhang, Y. et al. SWELL1 is a regulator of adipocyte size, insulin signalling and glucose homeostasis. Nat. Cell Biol. 19, 504–517 (2017).
pubmed: 28436964 pmcid: 5415409
Zhao, C. et al. Mechanosensitive Ion Channel Piezo1 Regulates Diet-Induced Adipose Inflammation and Systemic Insulin Resistance. Front Endocrinol. (Lausanne) 10, 373 (2019).
Kim, J. Y. et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest 117, 2621–2637 (2007).
pubmed: 17717599 pmcid: 1950456
Senol-Cosar, O. et al. Tenomodulin promotes human adipocyte differentiation and beneficial visceral adipose tissue expansion. Nat. Commun. 7, 10686 (2016).
pubmed: 26880110 pmcid: 4757769
Lee, Y. S. et al. Increased adipocyte O-2 consumption triggers HIF-1 alpha, Causing inflammation and insulin resistance in obesity. Cell 157, 1339–1352 (2014).
pubmed: 24906151 pmcid: 4114226
Reilly, S. M. & Saltiel, A. R. Adapting to obesity with adipose tissue inflammation. Nat. Rev. Endocrinol. 13, 633–643 (2017).
pubmed: 28799554
Crewe, C., An, Y. A. & Scherer, P. E. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J. Clin. Invest. 127, 74–82 (2017).
pubmed: 28045400 pmcid: 5199684
Sassmann-Schweda, A. et al. Increased apoptosis and browning of TAK1-deficient adipocytes protects against obesity. JCI Insight 1, e81175 (2016).
pubmed: 27699262 pmcid: 5033847
Chakraborty, D. et al. Fibroblast growth factor receptor is a mechanistic link between visceral adiposity and cancer. Oncogene 36, 6668–6679 (2017).
pubmed: 28783178 pmcid: 5709202
Wang, S. et al. Endothelial cation channel PIEZO1 controls blood pressure by mediating flow-induced ATP release. J. Clin. Invest 126, 4527–4536 (2016).
pubmed: 27797339 pmcid: 5127677
Retailleau, K. et al. Piezo1 in smooth muscle cells is involved in hypertension-dependent arterial remodeling. Cell Rep. 13, 1161–1171 (2015).
pubmed: 26526998
Peyronnet, R. et al. Piezo1-dependent stretch-activated channels are inhibited by Polycystin-2 in renal tubular epithelial cells. EMBO Rep. 14, 1143–1148 (2013).
pubmed: 24157948 pmcid: 3981085
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. Genesis 45, 593–605 (2007).
pubmed: 17868096
Sassmann, A., Offermanns, S. & Wettschureck, N. Tamoxifen-inducible Cre-mediated recombination in adipocytes. Genesis 48, 618–625 (2010).
pubmed: 20715175
Chen, H. C. & Farese, R. V. Jr. Determination of adipocyte size by computer image analysis. J. Lipid Res. 43, 986–989 (2002).
pubmed: 12032175
Bourgeois, F., Alexiu, A. & Lemonnier, D. Dietary-induced obesity: effect of dietary fats on adipose tissue cellularity in mice. Br. J. Nutr. 49, 17–26 (1983).
pubmed: 6821685

Auteurs

ShengPeng Wang (S)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany. shengpeng.wang@xjtu.edu.cn.
Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to Diseases, No.76 West Yanta Road, Yanta District, Xi'an, China. shengpeng.wang@xjtu.edu.cn.

Shuang Cao (S)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.
Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to Diseases, No.76 West Yanta Road, Yanta District, Xi'an, China.

Malika Arhatte (M)

Université Côte d'Azur, Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, Labex ICST, Valbonne, France.

Dahui Li (D)

The State Key Laboratory of Pharmaceutical Biotechnology, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong SAR, China.

Yue Shi (Y)

Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to Diseases, No.76 West Yanta Road, Yanta District, Xi'an, China.

Sabrina Kurz (S)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.

Jiong Hu (J)

Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany.

Lei Wang (L)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.

Jingchen Shao (J)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.

Ann Atzberger (A)

Max Planck Institute for Heart and Lung Research, Flow Cytometry Service Group, Ludwigstr. 43, 61231, Bad Nauheim, Germany.

Zheng Wang (Z)

Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Changhe Wang (C)

Center for Mitochondrial Biology and Medicine, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China.

Weijin Zang (W)

Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.

Ingrid Fleming (I)

Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany.

Nina Wettschureck (N)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany.
Center for Molecular Medicine, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.

Eric Honoré (E)

Université Côte d'Azur, Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, Labex ICST, Valbonne, France.

Stefan Offermanns (S)

Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231, Bad Nauheim, Germany. stefan.offermanns@mpi-bn.mpg.de.
Center for Molecular Medicine, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. stefan.offermanns@mpi-bn.mpg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH